GlassScriptPhysician profile
James Albert Day
NPI 1487667440
$2,445.66
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $131 · 2021: $638 · 2022: $1,166 · 2023: $220 · 2024: $14.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $235.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $436.98 | 2019-2023 | Ozempic, Rybelsus, Saxenda |
| Abbvie INC. | $391.15 | 2021-2023 | Vraylar |
| Pfizer INC. | $278.89 | 2019-2024 | |
| Amgen INC. | $206.89 | 2019-2023 | Otezla, Repatha |
| Lilly USA, LLC | $141.31 | 2021-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $132.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $112.67 | 2019-2023 | Farxiga |
| Abiomed | $99.18 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.89 | 2019-2022 | |
| Edwards Lifesciences Corporation | $65.55 | 2020-2021 | |
| Amarin Pharma, INC. | $63.85 | 2019-2022 | |
| Abbott Laboratories | $62.68 | 2021-2022 | |
| Medtronic, INC. | $56.73 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.33 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.35 | 2019-2021 | |
| Glaxosmithkline, LLC. | $31.31 | 2019-2021 | |
| Biogen, INC. | $17.10 | 2021 | |
| Dexcom, INC. | $15.57 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $12.98 | 2023 | Rexulti |
| Si-Bone, INC. | $12.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $11.89 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.86 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.82 | 2019 | |
| Inogen, INC. | $10.74 | 2022 | |
| Dynavax Technologies Corporation | $9.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.